AUDENTES THERAPEUTICS INC (BOLD) Covered Calls

You can sell covered calls on AUDENTES THERAPEUTICS INC to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for BOLD (prices last updated Fri 4:16 PM ET):

AUDENTES THERAPEUTICS INC (BOLD) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
33.04 -0.34 32.00 79.55 148K - 1.2B
Covered Calls For AUDENTES THERAPEUTICS INC (BOLD)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Sep 21 35 1.60 77.95 -55.1% -558.7%
Nov 16 35 3.40 76.15 -54.0% -214.2%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. The company was founded in 2012 and is headquartered in San Francisco, California.